Intuitive Surgical
ISRG
$414.52
+2.41%
Intuitive Surgical Inc. develops, manufactures, and markets the da Vinci robotic surgical system for minimally invasive procedures, along with the instruments, disposable accessories, and service contracts that generate recurring revenue across hospitals worldwide. With more than 11,000 da Vinci systems installed globally — including over 6,600 in the United States — the company is the undisputed category leader in soft-tissue surgical robotics, holding a dominant installed base that competitors such as Medtronic's Hugo platform have only recently begun to challenge. The current investor narrative is defined by a sharp tension: the company continues to post robust double-digit revenue growth and expanding margins, yet the stock has de-rated dramatically in 2026, falling roughly 30% year-to-date, as management declined to raise full-year guidance after a strong second quarter and investors worry about slowing procedure growth, rising competitive intensity, and a valuation that had priced in flawless execution. Recent headlines underscore this debate — Medtronic's FDA-approved Hugo robot is being framed as a long-term threat to Intuitive's moat, while analysts remain broadly constructive on the franchise even as the share price has broken down technically.…
ISRG
Intuitive Surgical
$414.52
Related headlines
Investment Opinion: Should I buy ISRG Today?
We rate ISRG a Hold, balancing its exceptional business quality and long-term growth potential against a premium valuation and near-term headwinds. The analyst consensus is Buy with an average target of $476.34, implying 21.5% upside, but the recent guidance disappointment and competitive threats warrant caution.
The supporting evidence includes a strong revenue growth of 18.54% YoY in Q2 2026, a net margin of 28.38%, and a robust free cash flow of $3.22 billion. The balance sheet is pristine with virtually no debt, and the installed base of over 11,000 systems provides a recurring revenue stream. However, the forward P/E of 32.4 and PEG of 3.17 are rich compared to the broader market, and the stock's 30.26% YTD decline reflects these concerns.
Key risks include the potential for slower procedure growth, Medtronic's Hugo gaining share, and further multiple compression. We would upgrade to Buy if the stock drops below $350 (forward P/E ~25x) or if procedure growth reaccelerates above 15%. We would downgrade to Sell if revenue growth falls below 10% or if Hugo significantly erodes Intuitive's market share. Relative to its history and peers, ISRG appears fairly valued after the recent sell-off, but not yet a bargain.
Sign up to view all
ISRG 12-Month Price Forecast
Intuitive Surgical remains a high-quality growth company with a dominant market position and strong financials, but it faces near-term headwinds from slowing procedure growth and rising competition. The stock's 30% YTD decline has brought valuation closer to fair, but not yet to bargain levels. We maintain a neutral stance, as the risk/reward is balanced. An upgrade to bullish would require evidence of reaccelerating procedure growth and successful defense against Medtronic. A downgrade to bearish would occur if procedure growth falls below 10% or if Hugo gains significant share.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $477.47 and implied upside of +15.2% versus the current price.
Average Target
$477.47
0 analysts
Implied Upside
+15.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$324 - $685
Analyst target range
Bulls vs Bears: ISRG Investment Factors
The bull case for Intuitive Surgical rests on its unmatched installed base, recurring revenue, and strong financials, while the bear case centers on its premium valuation, slowing growth, and competitive threats. Currently, the bear evidence appears stronger in the near term, given the stock's 30% YTD decline, guidance disappointment, and the emergence of Medtronic's Hugo. However, the long-term bull thesis remains intact if procedure growth reaccelerates and the company maintains its technological leadership. The single most important tension is whether Intuitive can sustain double-digit procedure growth amid rising competition; if it can, the stock is likely undervalued; if not, further multiple compression is likely.
Bullish
- Dominant Installed Base Moat: Intuitive has placed over 11,000 da Vinci systems globally, including 6,600 in the US, creating a massive recurring revenue stream from instruments and accessories. This installed base generates high-margin, predictable cash flows and presents a formidable barrier to entry for competitors like Medtronic's Hugo.
- Robust Revenue Growth and Margin Expansion: Q2 2026 revenue grew 18.54% YoY to $2.892 billion, with gross margin expanding to 67.78% from 66.31% a year earlier. Operating margin also improved to 33.6% from 30.5%, demonstrating strong operating leverage.
- Fortress Balance Sheet with No Debt: Debt-to-equity is just 0.017, and the current ratio is a healthy 4.87, indicating ample liquidity. The company generated $3.22 billion in trailing free cash flow, funding growth initiatives and potential buybacks without financial strain.
- Analyst Consensus Remains Bullish: Of 29 analysts covering ISRG, the average target price is $476.34, implying 21.5% upside from the current $391.95. The consensus recommendation is 'Buy' with a mean rating of 1.78, reflecting confidence in the long-term growth story.
Bearish
- Premium Valuation Leaves Little Room for Error: ISRG trades at a trailing P/E of 70.8 and a forward P/E of 32.4, well above the broader market and many healthcare peers. Its PEG ratio of 3.17 suggests the growth premium is steep, and any slowdown could trigger multiple compression.
- Slowing Procedure Growth and Guidance Disappointment: Management declined to raise full-year guidance after a strong Q2 2026, signaling caution on procedure growth. This, combined with a 30.26% YTD stock decline, indicates waning investor confidence in the near-term trajectory.
- Rising Competitive Threat from Medtronic: Medtronic's Hugo robot received FDA approval and is gaining traction, as highlighted by recent headlines. While Intuitive's installed base is a moat, Hugo's lower cost and Medtronic's global reach could pressure Intuitive's pricing and market share over time.
- High Beta and Significant Drawdown Risk: With a beta of 1.465, ISRG is more volatile than the market, and its max drawdown has been -44%. The stock has fallen 11.53% over the past year and 13.30% over six months, underperforming the S&P 500 significantly.
ISRG Technical Analysis
Beta
1.46
1.46x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$329-$604
Price range past year
Annual Return
-6.0%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | +13.0% | +0.9% |
| 3m | +0.7% | +3.4% |
| 6m | -8.0% | +14.4% |
| 1y | -6.0% | +16.2% |
| ytd | -26.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Quarterly Revenue
$2.9B
2026-06
Revenue YoY Growth
+18.5%
YoY Comparison
Gross Margin
67.8%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
PE
70.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 43x~85x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for Intuitive Surgical are relatively low given its debt-to-equity of 0.017 and current ratio of 4.87, but the company faces margin pressure from rising R&D expenses, which increased to $370.6 million in Q2 2026 from $313.3 million a year earlier. Revenue concentration in the da Vinci platform is a key risk, as any slowdown in system placements or procedure volumes would directly impact the high-margin instruments and accessories segment. Additionally, the company's growth relies on continued innovation, and any pipeline setbacks could hinder its ability to justify its premium valuation.
Market and competitive risks are significant, with ISRG trading at a forward P/E of 32.4 and a PEG of 3.17, leaving it vulnerable to valuation compression if growth decelerates. The beta of 1.465 indicates higher volatility than the market, and the stock has underperformed the S&P 500 by 26.5 percentage points over the past year. Medtronic's Hugo robot, recently FDA-approved, poses a long-term threat to Intuitive's dominance, potentially eroding pricing power and market share. Regulatory changes and hospital capital spending cycles could also impact system placements.
The worst-case scenario would involve a combination of slowing procedure growth, market share losses to Medtronic, and a broader market downturn, leading to a sharp de-rating. The 52-week low is $328.57, and the analyst low target is $324, representing a potential downside of 16-17% from the current price of $391.95. In a severe scenario, if growth stalls and the multiple compresses to 25x forward earnings, the stock could fall to the low $300s, implying a loss of over 20%. Investors should be prepared for significant drawdowns given the stock's historical max drawdown of -44%.
FAQ
The key risks include competitive threats from Medtronic's Hugo robot, which could erode Intuitive's market share and pricing power. Slowing procedure growth is another major risk, as the company's revenue depends on the number of surgeries performed. Valuation risk is significant, with a forward P/E of 32.4 leaving little room for error. Additionally, the stock has a high beta of 1.465, making it vulnerable to market downturns. Regulatory and reimbursement changes could also impact hospital spending on robotic systems.
Our 12-month forecast for ISRG includes a base case (55% probability) with a target range of $450-$500, a bull case (25% probability) of $550-$685, and a bear case (20% probability) of $300-$350. The base case assumes procedure growth stabilizes at 15-18% and the stock trades near the analyst average target of $476.34. The bull case hinges on reaccelerating growth and successful product launches, while the bear case assumes competitive losses and a growth slowdown. The most likely scenario is the base case, given the company's strong fundamentals and market position.
ISRG appears fairly valued after its 30% YTD decline, but it still trades at a premium to the broader market. The forward P/E of 32.4 is above the S&P 500 average, but below its own 5-year average of around 40x. The PEG ratio of 3.17 suggests the growth premium is still high. Compared to peers like Medtronic, which trades at a lower multiple, ISRG is expensive, but its superior growth and margins justify some premium. The market expects continued double-digit growth, and any disappointment could lead to further de-rating.
ISRG is a good buy for long-term investors with a high risk tolerance, given its dominant market position and strong financials. The stock trades at $391.95, with a forward P/E of 32.4 and an analyst average target of $476.34, implying 21.5% upside. However, near-term risks include slowing procedure growth and competition from Medtronic, which could pressure the stock. A good entry point would be below $350, where the valuation is more attractive. Investors should be prepared for volatility, as the beta is 1.465 and the stock has fallen 30% YTD.
ISRG is more suitable for long-term investment, given its wide moat, recurring revenue, and strong balance sheet. Short-term trading is risky due to the stock's high beta (1.465) and recent volatility, including a 30% YTD decline. The company does not pay a dividend, so returns depend on capital appreciation. A minimum holding period of 3-5 years is recommended to ride out industry cycles and benefit from the long-term growth in robotic surgery. Earnings visibility is moderate, with procedure growth being a key swing factor.